Daiwa Securities Group
OVID icon

Daiwa Securities Group’s Ovid Therapeutics OVID Stock Holding History

Daiwa Securities Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-119
Closed – – 1363
2022
Q3 		$0 Hold
119
– – ﹤0.01% 1373
2022
Q2 		$0 Hold
119
– – ﹤0.01% 1407
2022
Q1 		$0 Hold
119
– – ﹤0.01% 1404
2021
Q4 		$0 Hold
119
– – ﹤0.01% 1430
2021
Q3 		$0 Hold
119
– – ﹤0.01% 1333
2021
Q2 		$0 Hold
119
– – ﹤0.01% 1283
2021
Q1 		$0 Hold
119
– – ﹤0.01% 1282
2020
Q4 		$0 Buy
+119
New +$555 ﹤0.01% 1290

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Daiwa Securities Group's OVID Position: Q4 2022 in Review

Daiwa Securities Group sold out of Ovid Therapeutics (OVID) in Q4 2022, closing a stake of 119 shares.

Daiwa Securities Group first reported a position in OVID in Q4 2020 and held it in 8 quarters. The position peaked at $0 in Q3 2022. 60 funds tracked by Wall St. Rank hold OVID as of Q4 2022.

  • Daiwa Securities Group reported no remaining Ovid Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 119 Ovid Therapeutics shares in Q4 2022.
  • Daiwa Securities Group first reported a position in Ovid Therapeutics in Q4 2020 and held it in 8 quarters.
  • Daiwa Securities Group's Ovid Therapeutics position peaked at $0 in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.